North Dakota Attorney General · October 19, 2026 · Primary source
Attorney General Drew Wrigley Warns About Stem Cell Offers
What the document says
North Dakota Attorney General Drew H. Wrigley issued an advisory on October 19, 2026, warning residents about companies marketing unapproved stem cell treatments and human tissue injections through dinner sales presentations at local restaurants. The companies make claims that these therapies can cure, treat, or mitigate conditions including Parkinson's disease, diabetes, multiple sclerosis, Alzheimer's disease, autism, and dementia. The advisory characterizes these promotional claims as false and misleading and asserts they pose serious physical and financial harm to consumers. The advisory states that selling such treatments without FDA approval is unlawful under state and federal law. The AG noted that some companies claim to use FDA-registered facilities or to comply with FDA guidelines, but that neither registration nor guideline compliance constitutes approval of the marketed treatments. The FDA has taken prior enforcement actions against companies marketing unapproved stem cell products, and reported patient harms include life-threatening infections and chronic pain. The advisory specifically identifies Freedom Regenerative LLC as a company sending mailers to North Dakota residents inviting them to free dinner events where false and misleading claims about pain reduction and product efficacy are made. Freedom Regenerative LLC conducted business in North Dakota without a transient merchant license as required by state law. The company's offered treatments are priced between $9,000 and $29,000. The FTC previously found similar stem cell therapy sales presentations to constitute unfair and deceptive acts in violation of federal law that injured consumers. The AG's Consumer Protection and Antitrust Division is accepting complaints from individuals who purchased stem cell treatments under allegedly misleading or inaccurate representations.
What this may mean
Applies to companies marketing unapproved stem cell or human tissue injection products in North Dakota through direct-to-consumer sales events. Puts at issue compliance with FDA premarket approval requirements, FTC Act prohibitions on unfair and deceptive acts, and North Dakota transient merchant licensing obligations. Exposure includes state consumer protection enforcement and referral to federal agencies.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- North Dakota Attorney General · May 3, 2026The North Dakota Attorney General issued an opinion to the Department of Health and Human Services.Score 70
- North Dakota Attorney General · June 12, 2026ATTORNEY GENERAL WRIGLEY TO HOLD PRESS AVAILABILITY REGARDING FINAL SETTLEMENT IN ND v. UNITED STATESScore 23
- North Dakota Attorney General · June 12, 2026THE U.S. DEPARTMENT OF JUSTICE ISSUED THE FOLLOWING STATEMENT TODAY, IN RELATION TO THE FINAL SETTLEMENT OF NORTH DAKOTA V. UNITED STATES.Score 23
- North Dakota Attorney General · May 3, 2026ATTORNEY GENERAL WRIGLEY ANNOUNCES SETTLEMENT WITH COMPANY BEHIND DECEPTIVE INVOICE SOLICITATIONSScore 23
- North Dakota Attorney General · May 3, 2026The North Dakota Attorney General issued an opinion to the ND State AuditorScore 23
- North Dakota Attorney General · May 3, 2026The North Dakota Attorney General issued an opinion to the City of MandanScore 23